DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Anti-Cancer Drug Design

• Publication date

  1995-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 7748459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.

  1993cited by this paper
• Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.

  1993cited by this paper
• Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.

  1993cited by this paper
• Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.

  1991cited by this paper
• Training back-propagation neural networks to define and detect DNA-binding sites.

  1991cited by this paper
• Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

  1990cited by this paper
• Neural network detects errors in the assignment of mRNA splice sites.

  1990cited by this paper
• Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.

  1990cited by this paper
• Minimal DNA requirement for topoisomerase II-mediated cleavage in vitro.

  1990cited by this paper
• Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases.

  1990cited by this paper
• Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

  1989cited by this paper
• Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.

  1989cited by this paper
• DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage

  1989cited by this paper
• Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989cited by this paper
• Inhibitors of DNA topoisomerases.

  1988cited by this paper
• A consensus sequence for cleavage by vertebrate DNA topoisomerase II.

  1988cited by this paper
• Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

  1987cited by this paper
• DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.

  1986cited by this paper
• Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site.

  1985cited by this paper
• In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction.

  1985cited by this paper
• Identification of the breakage-reunion subunit of T4 DNA topoisomerase.

  1984cited by this paper
• Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

  1984cited by this paper
• Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II.

  1984cited by this paper
• DNA topoisomerases--enzymes that catalyse the breaking and rejoining of DNA.

  1983cited by this paper
• DNA gyrase and the supercoiling of DNA.

  1980cited by this paper
• Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

  1977cited by this paper
• Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

  1977cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Medicinal potential of ciprofloxacin and its derivatives.

  2013cites this paper
• Synthesis and topoisomerase inhibitory activities of novel aza-analogues of flavones 1 1 Part of the

  1999cites this paper
• Chemistry of Pyrido[2,1-c][1,4]oxazines, Pyrido[2,1- c][1,4]thiazines, Pyrido[1,2- a]pyrazines and T

  1998cites this paper
• DNA sequence selectivity of topoisomerases and topoisomerase poisons.

  1998cites this paper
• Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin.

  1997cites this paper
• Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).

  1996cites this paper
• Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta.

  1996cites this paper
• Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β

  1996cites this paper
• Topoisomerase II-mediated DNA cleavage: evidence for distinct regions of enzyme-DNA contacts.

  1996cites this paper
• Topoisomerase II as a target for anticancer chemotherapy.

  1995cites this paper